Electrolyte Disorders Associated With Cancer

Advances in Chronic Kidney Disease

Volumn 21, Issue 1, 2014, Pages 7-17

  Rosner, Mitchell H ^a   Dalkin, Alan C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cancer; Hypercalcemia; Hypokalemia; Hyponatremia; Hypophosphatemia

Indexed keywords

DISEASE ASSOCIATION; ELECTROLYTE DISTURBANCE; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; NEOPLASM; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CANCER; HYPERCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA;

HUMANS; INAPPROPRIATE ADH SYNDROME; NEOPLASMS; PARANEOPLASTIC SYNDROMES; WATER-ELECTROLYTE IMBALANCE;

EID: 84890671028     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.05.005     Document Type: Review

References (80)

1. Doshi S.M., Shah P., Lei X., Lahoti A., Salahudeen A.K. Hyponatremia is hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012, 59(2):222-228.
2. Berghmans T., Paesmans M., Body J.J. A prospective study on hyponatremia in medical cancer patients: epidemiology, etiology and differential diagnosis. Support Care Cancer 2000, 8(3):192-197.
3. Gill G., Huda B., Boyd A., et al. Characteristics and mortality of severe hyponatremia-a hospital-based study. Clin Endocrinol 2006, 65(2):246-249.
4. Dhaliwal H.S., Rohatiner A.Z.S., Gregory W., et al. Combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma. Br J Cancer 1993, 68(4):767-774.
5. Osterlund K. Factors confounding evaluation and treatment effect in lung cancer. Lung Cancer 1994, 10(suppl 1):S97-S103.
6. Gross A.J., Steiberg S.M., Reilly J.G., et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993, 53(1):67-74.
7. Waikar S.S., Mount D.B., Curhan G.C. Mortality after hospitalization with mild, moderate and severe hyponatremia. Am J Med 2009, 122(9):857-865.
8. Wald R., Jaber B.L., Price L.L., Upadhyay A., Madias N.E. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010, 170(3):294-302.
9. Chawla A., Sterns R.H., Nigwekar S.U., Cappuccio J.D. Mortality and serum sodium: do patients die from or with hyponatremia. Clin J Am Soc Nephrol 2011, 6(5):960-965.
10. Hansen O., Sorensen P., Hansen K.H. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010, 68(1):111-114.
11. Schwartz W.B., Bennett W., Curelop S., Bartter F.C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957, 23(12):529-542.
12. Comis R., Miller M., Ginsberg S. Abnormalities in water homeostasis in small cell anaplastic lung cancer. Cancer 1980, 45(9):2414-2421.
13. Padfield P., Morton J., Brown J., et al. Plasma arginine vasopressin in the syndrome of antidiuretic hormone excess associated with bronchogenic carcinoma. Am J Med 1976, 61(6):825-831.
14. Biran H., Feld R., Sagman U., et al. Carcinoembryonic antigen, arginine vasopressin and calcitonin as markers of early small cell lung cancer relapse. Tumour Biol 1989, 10(5):258-267.
15. List A.F., Hainsworth J.D., Davis B.W., Hande K.R., Greco F.A., Johnson D.H. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986, 4(8):1191-1198.
16. Pettengill O., Faulkner C., Wurster-Hill D., et al. Isolation and characterization of a hormone-producing cell line from human small cell anaplastic carcinoma of the lung. J Natl Cancer Inst 1977, 58(3):511-516.
17. Osterlind K., Andersen P. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986, 46(8):4189-4194.
18. Osterlind K., Hansen H.H., Dombernowsky P. Determinants of complete remission induction and maintenance in chemotherapy with or without radiation of small cell lung cancer. Cancer Res 1987, 47(10):2733-2736.
19. Souhami R.I., Bradbury I., Geddes D.M., et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 1985, 45(6):2878-2882.
20. Sethi T., Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin and neurotensin. Cancer Res 1991, 51(13):3621-3623.
21. Ferlito A., Rinaldo A., Devaney K.O. Syndrome of inappropriate antidiuretic hormone secretion associated with head and neck cancers: review of the literature. Ann Otol Rhinol Laryngol 1997, 106(10 Pt 1):878-883.
22. Berghmans T. Hyponatremia related to medical anticancer treatment. Support Care Cancer 1996, 4(5):341-350.
23. Hamdi T., Latta S., Jallad B., et al. Cisplatin-induced renal salt wasting syndrome. South Med J 2010, 103(8):793-799.
24. Bissram M., Scott F.D., Rosner M.H. Risk factors for symptomatic hyponatremia: the role of pre-existing asymptomatic hyponatremia. Intern Med J 2007, 37(3):149-155.
25. Kimura T., Abe K., Ota K., et al. Effects of acute water load, hypertonic saline infusion and furosemide administration on atrial natriuretic peptide and vasopressin release in humans. J Clin Endocrinol Metab 1986, 62(5):1003-1010.
26. Weinand M.E., O'Boynick P.L., Goetz K.L. A study of serum antidiuretic hormone and atrial natriuretic peptide levels in a series of patients with intracranial disease and hyponatremia. Neurosurgery 1989, 25(5):781-785.
27. Manning P. Vasopressin-stimulated releases of atriopeptin: endocrine antagonists in fluid homeostasis. Science 1985, 229(4711):395-397.
28. Kamoi K., Ebe T., Hasegawa A., et al. Hyponatremia in small cell lung cancer. Mechanism not involving inappropriate AVP secretion. Cancer 1987, 60(5):1089-1093.
29. Bliss D.A.J., Battey J.F., Linnoila R.J., et al. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 1990, 82(4):305-310.
30. Verbalis J.G., Goldsmith S.R., Greenberg A., Schrier R.W., Sterns R.H. Hyponatremia treatment guidelines 2007. Expert panel recommendations. Am J Med 2007, 120(11 suppl 1):S1-S21.
31. 2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355(20):2099-2112. SALT Investigators.
32. Verbalis J.G., Adler S., Schrier R.W., et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011, 164(5):725-732.
33. Sevastos N., Theodossiades G., Archimandritis A.J. Pseudohyperkalemia in serum: a new insight into an old phenomenon. Clin Med Res 2008, 6(1):30-32.
34. Abraham B., Fakhar I., Tikaria A., et al. Reverse pseudohyperkalemia in a leukemic patient. Clin Chem 2008, 54(2):449-551.
35. O'Regan S., Carson S., Chesney R.W., Drummond K.N. Electrolyte and acid-base disturbance in the management of leukemia. Blood 1977, 49(3):345-353.
36. Aldinger S., Samaan N.A. Hypokalemia with hypercalcemia. Prevalence and significance in treatment. Ann Intern Med 1977, 87(5):571-573.
37. Naparstek Y., Gutman A. Case report: spurious hypokalemia in myeloproliferative disorders. Am J Med Sci 1984, 288(4):175-177.
38. Isidori A.M., Kaltsas G.A., Grossman A.B. Ectopic ACTH syndrome. Front Horm Res 2006, 35:143-156.
39. Hernandez I., Espinosa-de-los-Monteros A.L., Mendoza V., et al. Ectopic ACTH-secreting syndrome: a single center experience report with a high prevalence of occult tumor. Arch Med Res 2006, 37(8):976-980.
40. Milionis H.J., Bourantas C.L., Siamopoulos K.C., Elisaf M.S. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol 1999, 62(4):201-207.
41. Mason D.Y., Howes D.T., Taylor C.R., Ross B.D. Effect of human lysozyme (muramidase) on potassium handling by the perfused rat kidney. A mechanism for renal damage in human monocytic leukaemia. J Clin Pathol 1975, 28(9):722-727.
42. Unwin R.J., Luft F.C., Shirley D.G. Pathophysiology and management of hypokalemia: a clinical perspective. Nat Rev Nephrol 2011, 7(2):75-84.
43. Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D and FGF23. Annu Rev Med 2010, 61:91-104.
44. Marks J., Debnam E.S., Unwin R.J. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Ren Physiol 2010, 299(2):F285-F296.
45. Berndt T., Thomas L.F., Craig T.A., et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci U S A 2007, 104(26):11085-11090.
46. Wilz D.R., Gray R.W., Dominguez J.H., Lemann J. Plasma 1,25-(OH)2-vitamin D concentrations and net intestinal calcium, phosphate, and magnesium absorption in humans. Am J Clin Nutr 1979, 32(10):2052-2060.
47. Sommer S., Berndt T., Craig T., Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 2007, 103(3-5):497-503.
48. Katai K., Miyamoto K., Kishida S., et al. Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1,25-dihydroxyvitamin D3. Biochem J 1999, 343(Pt 3):705-712.
49. Juppner H., Gardella T.J., Brown E.M., et al. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development. Endocrinology 2006, 1377-1417. Elsevier Saunders, Philadelphia, PA. L.J. DeGroot, J.L. Jameson (Eds.).
50. Foster I.C., Hernando N., Biber J., Murer H. Proximal tubular handling of phosphate: a molecular perspective. Kidney Int 2006, 70(9):1548-1559.
51. Juppner H., Wolf M., Salusky I.B. FGF-23: more than a regulator of renal phosphate handling?. J Bone Miner Res 2010, 25(10):2091-2097.
52. Kurosu H., Ogawa Y., Miyoshi M., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006, 281(10):6120-6123.
53. Urakawa I., Yamazaki Y., Shimada T., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444(7120):770-774.
54. Nishi H., Nii-Kono T., Nakanishi S., et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005, 101(2):c94-c99.
55. Burnett S.M., Gunawardene S.C., Bringhurst F.R., et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006, 21(8):1187-1196.
56. Inoue Y., Segawa H., Kaneko I., et al. Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 2005, 390(Pt 1):325-331.
57. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008, 118(12):3820-3828.
58. Chong W.H., Molinolo A.A., Chen C.C., Collins M.T. Tumor-induced osteomalacia. Endocr Relat Cancer 2011, 18(3):R53-R77.
59. Andreopoulou P., Millo C., Reynolds J., et al. Multimodality diagnosis and treatment of tumor induced osteomalacia. Endocr Rev 2010, 31(suppl 1). OR08-6S49.
60. Andreopoulou P., Dumitrescu C.E., Kelly M.H., et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 2011, 26(6):1295-1302.
61. Khosravi A., Cutler C.M., Kelly M.H., et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab 2007, 92(6):2374-2377.
62. Clunie G.P., Fox P.E., Stamp T.C. Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology 2000, 39(12):1415-1421.
63. Ogose A., Hotta T., Emura I., et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol 2001, 30(2):99-103.
64. Stewart A.F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005, 352(4):373-379.
65. Labriola L., Wallemacq P., Gulbis B., Jadoul M. The impact of the assay for measuring albumin on corrected ('adjusted') calcium concentrations. Nephrol Dial Transplant 2009, 24(6):1834-1838.
66. Saburo S., Yano S. Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. Cancer Metastasis Rev 2007, 26(3-4):685-689.
67. Grill V., Ho P., Body J.J., et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991, 73(6):1309-1315.
68. Sourbier C., Massfelder T. Parathyroid hormone-related protein in human renal cell carcinoma. Cancer Lett 2006, 240(2):170-182.
69. Chen Y.C., Sosnoski D.M., Mastro A.M. Breast cancer metastasis to thebone: mechanisms of bone loss. Breast Cancer Res 2010, 12(6):215-226.
70. Clines G.A. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes 2011, 18(6):339-346.
71. Abilgard N., Brixen K., Eriksen E.F., Kristensen J.E., Nilsen J.L., Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004, 89(5):567-577.
72. Seymour J.F., Gagel R.F. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1993, 82(5):1383-1394.
73. Rosner M., Dalkin A. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol 2012, 7(10):1722-1729.
74. LeGrand S., Leskuski D., Zama I. Narrative review: furosemide for hypercalcemia: an unproven, yet common practice. Ann Intern Med 2008, 149(4):259-263.
75. Rogers M.J., Gordon S., Benford H., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88(suppl 12):2961-2978.
76. Brown-Glaberman U., Stopeck A.T. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors. Biologics 2012, 6:89-99.
77. Castellano D., Sepulveda J.M., Garcia-Escobar I., Rodriguez-Antolin A., Sundlov A., Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 2011, 16(2):136-145.
78. Bilezkian J.P. Management of acute hypercalcemia. N Engl J Med 1992, 326(18):1196-1203.
79. Fokkema M.I., de Heide L.J.M., van Schelven W.E., Hamdy N.A.T. Severe hypocalcemia associated with extensive osteoblastic metastases in a patient with prostate cancer. Neth J Med 2005, 63(1):34-37.
80. Yener S., Demir O., Ozdogan O., Akinci B., Yesil S. Severe hypocalcaemia because of osteoblastic prostate carcinoma metastases. Int J Clin Pract 2008, 62(10):1630-1631.